Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice

Vaccine

Volumn 29, Issue 20, 2011, Pages 3646-3654

  Orlandi, Francesca ^a,b   Guevara Patiño, José A ^a,c   Merghoub, Taha ^a   Wolchok, Jedd D ^a   Houghton, Alan N ^a   Gregor, Polly D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Aureon Biosciences   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Breast cancer; DNA vaccine; HER2 neu; Immunotherapy

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; EPITOPES; FEMALE; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; RECEPTOR, ERBB-2; VACCINES, DNA;

EID: 79955118680     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.017     Document Type: Article

References (42)

1. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine 2001, 344(March (11)):783-792.
2. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 2002, 20(February (3)):719-726.
3. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine 2005, 353(October (16)):1659-1672.
4. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Research 2006, 8(6):215.
5. Naftzger C., Takechi Y., Kohda H., Hara I., Vijayasaradhi S., Houghton A.N. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(December (25)):14809-14814.
6. Hawkins W.G., Gold J.S., Blachere N.E., Bowne W.B., Hoos A., Lewis J.J., et al. Xenogeneic DNA immunization in melanoma models for minimal residual disease. The Journal of Surgical Research 2002, 102(February (2)):137-143.
7. Gregor P.D., Wolchok J.D., Turaga V., Latouche J.B., Sadelain M., Bacich D., et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. International Journal of Cancer 2005, 116(September (3)):415-421.
8. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research 2003, 9(April (4)):1284-1290.
9. Bergman P.J., Camps-Palau M.A., McKnight J.A., Leibman N.F., Craft D.M., Leung C., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24(May (21)):4582-4585.
10. Barouch D.H., Letvin N.L., Seder R.A. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunological Reviews 2004, 202(December):266-274.
11. Calarota S.A., Weiner D.B. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunological Reviews 2004, 199(June):84-99.
12. Ferrone C.R., Perales M.A., Goldberg S.M., Somberg C.J., Hirschhorn-Cymerman D., Gregor P.D., et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clinical Cancer Research 2006, 12(September (18)):5511-5519.
13. Stevenson F.K., Rice J., Ottensmeier C.H., Thirdborough S.M., Zhu D. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunological Reviews 2004, 199(June):156-180.
14. Engelhorn M.E., Guevara-Patino J.A., Merghoub T., Liu C., Ferrone C.R., Rizzuto G.A., et al. Mechanisms of immunization against cancer using chimeric antigens. Molecular Therapy 2008, 16(April (4)):773-781.
15. Houghton A.N., Guevara-Patino J.A. Immune recognition of self in immunity against cancer. The Journal of Clinical Investigation 2004, 114(August (4)):468-471.
16. Guevara-Patino J.A., Engelhorn M.E., Turk M.J., Liu C., Duan F., Rizzuto G., et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. The Journal of Clinical Investigation 2006, 116(May (5)):1382-1390.
17. Houghton C.S., Engelhorn M.E., Liu C., Song D., Gregor P., Livingston P.O., et al. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 2007, 25(July (29)):5330-5342.
18. Saenger Y.M., Li Y., Chiou K.C., Chan B., Rizzuto G., Terzulli S.L., et al. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Research 2008, 68(December (23)):9884-9891.
19. Reilly R.T., Machiels J.P., Emens L.A., Ercolini A.M., Okoye F.I., Lei R.Y., et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Research 2001, 61(February (3)):880-883.
20. Wolpoe M.E., Lutz E.R., Ercolini A.M., Murata S., Ivie S.E., Garrett E.S., et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. Journal of Immunology 2003, 171(August (4)):2161-2169.
21. Orlandi F., Venanzi F.M., Concetti A., Yamauchi H., Tiwari S., Norton L., et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clinical Cancer Research 2007, 13(October (20)):6195-6203.
22. Disis M.L., Wallace D.R., Gooley T.A., Dang Y., Slota M., Lu H., et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. Journal of Clinical Oncology 2009, 27(October (28)):4685-4692.
23. Norell H., Poschke I., Charo J., Wei W.Z., Erskine C., Piechocki M.P., et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. Journal of Translational Medicine 2010, 8:53.
24. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular and Cellular Biology 1989, 9(March (3)):1165-1172.
25. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(May (10)):4285-4289.
26. Zhang H., Wang Q., Montone K.T., Peavey J.E., Drebin J.A., Greene M.I., et al. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Experimental and Molecular Pathology 1999, 67(September (1)):15-25.
27. Rovero S., Amici A., Di Carlo E., Bei R., Nanni P., Quaglino E., et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. Journal of Immunology 2000, 165(November (9)):5133-5142.
28. Ross H.M., Weber L.W., Wang S., Piskun G., Dyall R., Song P., et al. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clinical Cancer Research 1997, 3(December (12 Pt 1)):2191-2196.
29. Weber L.W., Bowne W.B., Wolchok J.D., Srinivasan R., Qin J., Moroi Y., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. The Journal of Clinical Investigation 1998, 102(September (6)):1258-1264.
30. Kowalczyk D.W., Wlazlo A.P., Blaszczyk-Thurin M., Xiang Z.Q., Giles-Davis W., Ertl H.C. A method that allows easy characterization of tumor-infiltrating lymphocytes. Journal of Immunological Methods 2001, 253(July (1-2)):163-175.
31. Zanoni I., Ostuni R., Capuano G., Collini M., Caccia M., Ronchi A.E., et al. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 2009, 460(July (7252)):264-268.
32. zum Buschenfelde C.M., Hermann C., Schmidt B., Peschel C., Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Research 2002, 62(April (8)):2244-2247.
33. Drebin J.A., Link V.C., Stern D.F., Weinberg R.A., Greene M.I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41(July (3)):697-706.
34. Klapper L.N., Waterman H., Sela M., Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Research 2000, 60(July (13)):3384-3388.
35. Kono K., Sato E., Naganuma H., Takahashi A., Mimura K., Nukui H., et al. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clinical Cancer Research 2004, 10(April (7)):2538-2544.
36. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine 2000, 6(April (40)):443-446.
37. Curcio C., Di Carlo E., Clynes R., Smyth M.J., Boggio K., Quaglino E., et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. The Journal of Clinical Investigation 2003, 111(April (8)):1161-1170.
38. Rovero S., Boggio K., Di Carlo E., Amici A., Quaglino E., Porcedda P., et al. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Therapy 2001, 8(March (6)):447-452.
39. Rolla S., Nicolo C., Malinarich S., Orsini M., Forni G., Cavallo F., et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. Journal of Immunology 2006, 177(December (11)):7626-7633.
40. Disis M.L., Calenoff E., McLaughlin G., Murphy A.E., Chen W., Groner B., et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Research 1994, 54(January (1)):16-20.
41. Disis M.L., Knutson K.L., Schiffman K., Rinn K., McNeel D.G. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Research and Treatment 2000, 62(August (3)):245-252.
42. Park S., Jiang Z., Mortenson E.D., Deng L., Radkevich-Brown O., Yang X., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18(August (2)):160-170.